Cargando…

Propiverine Hydrochloride as a Treatment for Fecal Incontinence

PURPOSE: Propiverine hydrochloride (PH) is widely used for the treatment of urinary incontinence (UI) due to bladder overactivity. Moreover, the comorbidity of UI with fecal incontinence (FI) is known to be due to the relationship of both to nervous system disorders and dysfunction or weakening of t...

Descripción completa

Detalles Bibliográficos
Autores principales: Irei, Yasue, Takano, Shota, Yamada, Kazutaka
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Korean Society of Coloproctology 2020
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7299569/
https://www.ncbi.nlm.nih.gov/pubmed/32178499
http://dx.doi.org/10.3393/ac.2019.09.30.2
_version_ 1783547413535916032
author Irei, Yasue
Takano, Shota
Yamada, Kazutaka
author_facet Irei, Yasue
Takano, Shota
Yamada, Kazutaka
author_sort Irei, Yasue
collection PubMed
description PURPOSE: Propiverine hydrochloride (PH) is widely used for the treatment of urinary incontinence (UI) due to bladder overactivity. Moreover, the comorbidity of UI with fecal incontinence (FI) is known to be due to the relationship of both to nervous system disorders and dysfunction or weakening of the pelvic floor muscles. The aim of this single-arm prospective study was to evaluate the therapeutic value of PH for FI. METHODS: Patients (n = 24) who were diagnosed as having both FI and UI from April 2015 to November 2016 were included in the study and administered a dosage of 10–20 mg PH every day for 1 month. The primary endpoint was to create a reduction in the frequency of FI per week. An evaluation criterion of ≥50% reduction in frequency was determined as effective. The percentage of the patients who achieved the ≥50% endpoint (responders) was also calculated. RESULTS: The frequency of FI per week was 6.0 ± 8.2 (0.25–30) at baseline and reduced to 1.6 ± 2.1 (0–7) at the posttherapeutic state (P = 0.005). A reduction of ≥50% was seen in 14 of the patients (58.3%). CONCLUSION: PH reduced the frequency of FI in patients with both FI and UI. This study introduces a possible therapeutic option for the pharmacological treatment of FI.
format Online
Article
Text
id pubmed-7299569
institution National Center for Biotechnology Information
language English
publishDate 2020
publisher Korean Society of Coloproctology
record_format MEDLINE/PubMed
spelling pubmed-72995692020-06-19 Propiverine Hydrochloride as a Treatment for Fecal Incontinence Irei, Yasue Takano, Shota Yamada, Kazutaka Ann Coloproctol Original Article PURPOSE: Propiverine hydrochloride (PH) is widely used for the treatment of urinary incontinence (UI) due to bladder overactivity. Moreover, the comorbidity of UI with fecal incontinence (FI) is known to be due to the relationship of both to nervous system disorders and dysfunction or weakening of the pelvic floor muscles. The aim of this single-arm prospective study was to evaluate the therapeutic value of PH for FI. METHODS: Patients (n = 24) who were diagnosed as having both FI and UI from April 2015 to November 2016 were included in the study and administered a dosage of 10–20 mg PH every day for 1 month. The primary endpoint was to create a reduction in the frequency of FI per week. An evaluation criterion of ≥50% reduction in frequency was determined as effective. The percentage of the patients who achieved the ≥50% endpoint (responders) was also calculated. RESULTS: The frequency of FI per week was 6.0 ± 8.2 (0.25–30) at baseline and reduced to 1.6 ± 2.1 (0–7) at the posttherapeutic state (P = 0.005). A reduction of ≥50% was seen in 14 of the patients (58.3%). CONCLUSION: PH reduced the frequency of FI in patients with both FI and UI. This study introduces a possible therapeutic option for the pharmacological treatment of FI. Korean Society of Coloproctology 2020-04 2020-03-16 /pmc/articles/PMC7299569/ /pubmed/32178499 http://dx.doi.org/10.3393/ac.2019.09.30.2 Text en Copyright © 2020 The Korean Society of Coloproctology This is an Open Access article distributed under the terms of the Creative Commons Attribution Non-Commercial License (http://creativecommons.org/licenses/by-nc/4.0/) which permits unrestricted non-commercial use, distribution, and reproduction in any medium, provided the original work is properly cited.
spellingShingle Original Article
Irei, Yasue
Takano, Shota
Yamada, Kazutaka
Propiverine Hydrochloride as a Treatment for Fecal Incontinence
title Propiverine Hydrochloride as a Treatment for Fecal Incontinence
title_full Propiverine Hydrochloride as a Treatment for Fecal Incontinence
title_fullStr Propiverine Hydrochloride as a Treatment for Fecal Incontinence
title_full_unstemmed Propiverine Hydrochloride as a Treatment for Fecal Incontinence
title_short Propiverine Hydrochloride as a Treatment for Fecal Incontinence
title_sort propiverine hydrochloride as a treatment for fecal incontinence
topic Original Article
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7299569/
https://www.ncbi.nlm.nih.gov/pubmed/32178499
http://dx.doi.org/10.3393/ac.2019.09.30.2
work_keys_str_mv AT ireiyasue propiverinehydrochlorideasatreatmentforfecalincontinence
AT takanoshota propiverinehydrochlorideasatreatmentforfecalincontinence
AT yamadakazutaka propiverinehydrochlorideasatreatmentforfecalincontinence